Dr. Jayna Doshi, MD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 10240 Park Meadows Dr, Lone Tree, CO 80124 Phone: 303-338-4545 |
Dr. Michael L Lunn, D.O. Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 10240 Park Meadows Dr, Lone Tree, CO 80124 Phone: 303-338-4545 |
Diane Pincus, MD Allergy & Immunology Medicare: Not Enrolled in Medicare Practice Location: 1925 W Mountain View Ave, Longmont, CO 80501 Phone: 303-776-1234 Fax: 720-494-3107 |
Dr. Shoban Arun Dave, MD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 90 Health Park Dr, Suite 170, Louisville, CO 80027 Phone: 303-862-3303 Fax: 303-862-3308 |
Ashok R Patel, MD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 540 E Abriendo Ave Ste D, Pueblo, CO 81004 Phone: 719-542-7222 |
Mr. Ganapathy Bala, MD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 1315 S Pueblo Blvd, Pueblo, CO 81005 Phone: 719-561-9757 Fax: 719-561-9764 |
Diane Christina Napoli, M.D. Allergy & Immunology Medicare: Medicare Enrolled Practice Location: 1000 Rush Dr, Salida, CO 81201 Phone: 719-530-2000 |
News Archive
For-profit hospitals are out-performing other hospitals when treating stroke, heart attack and pneumonia patients in emergency departments and, thus, will be more likely to receive bonuses under Medicare's new payment rules, according to a new Northwestern Medicine- study.
Finding ways to counteract or disrupt the invasive nature of cancer cells, called "metastasis," has been a long-term goal of cancer researchers. Now, researchers at Moffitt Cancer Center in Tampa, Fla., have identified an interactive pathway that regulates metastases in some cancers that may be vulnerable to chemical targeting in order to prevent cancer cell proliferation and tumor growth.
A new paper published by McGill University researchers in JAMA Internal Medicine suggests that some clinical trials may promote the use of ineffective and costly treatments. That's the opposite of what clinical trials are aimed at, namely preventing ineffective and costly treatments from being taken up by physicians and patients.
Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, announced today that it has received commitments from institutional investors to purchase US$12.1 million of securities in a registered direct offering.
› Verified 4 days ago